Pharmacogenomics and the future of toxicology testing.

TitlePharmacogenomics and the future of toxicology testing.
Publication TypeJournal Article
Year of Publication2012
AuthorsAgrawal YPal, Rennert H
JournalClin Lab Med
Date Published2012 Sep
KeywordsAutopsy, Databases, Genetic, Drug Labeling, Humans, Pharmaceutical Preparations, Pharmacogenetics, Toxicity Tests

Pharmacogenomics is a useful tool in clinical toxicology for characterizing many gene polymorphisms associated with different pharmacokinetics or pharmacodynamics of exogenously administered drugs. These genetic variants may determine ranges of variation in such fundamental aspects as drug-metabolizing enzymes, drug transporters, drug receptors, or targets of drug action. Toxicologically significant drugs for which the FDA has required the manufacturer to identify relevant pharmacogenomics markers on the label include carisoprodol, citalopram, codeine, and risperidone. For personalized medicine, combining pharmacogenomics testing with therapeutic drug monitoring may allow the identification of individuals who need lower or higher doses, or even a different drug.

Alternate JournalClin Lab Med
PubMed ID22939305
Related Lab: 
Related Faculty: 
Hanna Rennert, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700